Cladribine, cytarabine, and venetoclax-based regimens are associated with durable remissions in patients (pts) with newly diagnosed Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation
Retrospective study shows high durable remission rates in acute myeloid leukemia with cladribine and venetoclax, indicating potential for allogeneic stem cell transplantation benefits.
Key Points
Durable remission rates were achieved in older patients with newly diagnosed Acute Myeloid Leukemia and cladribine combined with venetoclax.
Patients showed a 3-year overall survival rate of 78% following allogeneic stem cell transplantation.
Retrospective analysis of 303 patients indicated effective use of intensive and low-intensity therapy regimens.
Outcomes highlight the importance of tailored maintenance therapy following allogeneic stem cell transplantation.